Welcome to our dedicated page for Cumberland Pharmaceuticals SEC filings (Ticker: CPIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cumberland Pharmaceuticals Inc. filings document a specialty pharmaceutical issuer with branded prescription products and clinical-development programs. The company's 8-K reports cover operating and financial results, FDA and clinical regulatory updates, material agreements, credit-facility amendments, capital-structure disclosures and other material events tied to its pharmaceutical portfolio.
Proxy materials and annual-meeting reports disclose board elections, auditor ratification, advisory compensation votes, executive compensation, beneficial ownership, corporate governance and shareholder proposal procedures. Financing-related filings describe revolving credit obligations, borrowing covenants, collateral arrangements and related debt disclosures.
Jones James reported acquisition or exercise transactions in this Form 4 filing.
Cumberland Pharmaceuticals director James Jones received a stock grant as part of his compensation. He was awarded 1,800 shares of Common Stock at a value of $2.80 per share. Following this grant, he directly owns 46,863 shares, indicating a routine, compensation-related increase in his holdings.
Cumberland Pharmaceuticals director Kenneth Krogulski received stock awards totaling 5,800 shares of common stock. The grants were recorded at a price of $2.80 per share on March 18, 2026. Following these award acquisitions, he directly holds 302,338 shares of Cumberland Pharmaceuticals common stock.
Cumberland Pharmaceuticals director Caroline Young received a grant of 1,800 shares of Common Stock of CUMBERLAND PHARMACEUTICALS INC. The shares were awarded at a price of $2.80 per share. Following this compensation-related acquisition, she directly holds 35,109 shares of the company’s common stock.
Cumberland Pharmaceuticals vice president receives new stock options grant. Vice President of Organizational Development Anthony Todd M. was granted options to acquire 3,000 shares of Cumberland Pharmaceuticals common stock at an exercise price of $2.80 per share. These options become exercisable on March 18, 2030 and expire on March 18, 2036. Following this award, his reported derivative holdings total 21,000 options.
Bitterman Chris T. reported acquisition or exercise transactions in this Form 4 filing.
Cumberland Pharmaceuticals vice president of sales and marketing Chris T. Bitterman received a grant of options to buy 3,000 shares of common stock at $2.80 per share. These options become exercisable on March 18, 2030 and expire on March 16, 2036. Following this award, he holds options covering 19,000 shares in total.
Cumberland Pharmaceuticals Vice President and Chief Financial Officer John M. Hamm received a grant of 3,000 stock options on March 18, 2026. These options carry an exercise price of $2.80 per share and expire on March 18, 2036, bringing his reported option holdings to 18,250 shares.
Cumberland Pharmaceuticals executive James L. Herman received a grant of 2,500 stock options linked to the company’s common stock. The options carry an exercise price of 2.80 per share, become exercisable on 2030-03-18, and expire on 2036-03-18.
After this award, Herman holds a total of 21,000 options directly. This is a routine compensation-related grant rather than an open-market purchase or sale, so it does not reflect new trading activity in the company’s stock.
Cumberland Pharmaceuticals Chairman and CEO A. J. Kazimi received a grant of stock options covering 100,000 shares of common stock at an exercise price of $2.8000 per share. After this award, he holds options for a total of 568,000 shares, reflecting compensation rather than an open-market purchase.
Cumberland Pharmaceuticals chairman and CEO A.J. Kazimi reported a tax-related share disposition. On this Form 4, 5,845 shares of Common Stock were withheld at $3.06 per share to cover tax obligations. After this non-market transaction, he directly holds 5,695,310 shares of Cumberland Pharmaceuticals.